利拉鲁肽治疗新发的1型糖尿病8例效果观察(2)
第1页 |
参见附件。
[4] Degn KB.One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211)markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes[J]. Diabetes,2004,53:1187-1194.
[5] Creutzfeldt WO,Kleine N,Willms B,et al.Oucogontatic actions and reduction of fasting hyperglycemia by exogenous glucogon-like peptidel(7-36)amide in type 1 diabetic patients[J].Diabetes Care,1996,19:580-586.
[6] Behme MT,Dupre J,McDonald TJ,et al.Glucagun-like peptide limproved glycemic control in type l diabetes[J].BMC Endocr Disord,2003,10:1-9.
[7] Gutniak M,Orskov C, Hoist JJ,et al.Antidiabetogenie effect of Glucagon-like peptide-1(7-36)amide in normal subjects and patients with diabetes mellitus[J].N Engl J Med,1992,326:1316-1322.
[8] Ghofaili KA,Fung M,Ao Z,et al.Effect of exenatide on 8 eel function afar islet transplantation in type diabetes[J].Transplantation,2007,83:24-28.
(收稿日期:2013-03-18)
您现在查看是摘要介绍页,详见PDF附件。